Treatment of Chronic Cholestasis: What We Know and What We Will Know?
|
|
- Jade Wright
- 6 years ago
- Views:
Transcription
1 REVIEW Treatment of Chronic Cholestasis: What We Know and What We Will Know? James L. Boyer HISTORICAL PERSPECTIVES For many years, the treatment of cholestatic liver disease was limited to surgical relief of bile duct obstruction and therapies that focused on symptomatic relief from pruritus and other complications of these diseases. The mainstay for treatment of pruritus was and still is the administration of the anion exchange resin, cholestyramine. 1 Alternative therapies such as rifampin, a cytochrome p-450 Cyp3A microsomal enzyme inducer, were introduced 2 with some success. Less benefit came from third-line treatments that included opiate receptor antagonists (naltrexone and nalmefene) 3 and more heroic measures that included plasmapheresis, charcoal hemoperfusion, and more recently, MARS. 4 Treatment for complications of cholestasis focused on prevention/reduction in progression of osteoporosis with the use of bisphosphonates, risedronate and alendronate. Fat-soluble vitamin deficiencies brought on by the impaired excretion of bile acids (BAs) and the resulting steatorrhea called for supplementation with vitamin D to prevent osteomalacia, vitamin K for the coagulopathy brought about by malabsorption of vitamin K, and vitamin A for night blindness, mostly observed in pediatric causes of cholestasis. The demonstration by Poupon and associates 5 in 1997 that ursodeoxycholic acid seemed to prolong the course of patients with primary biliary cirrhosis (PBC) provided the first and only medication at that time for primary treatment of a cholestatic disease. Although the U.S. Abbreviations: A 2, anion; ABCC4, ATP-binding cassette subfamily C member 4; ABST, apical sodium-dependent bile salt transporter; AE2, anion exchange protein 2; BA, bile acid; BS 2, bile salts; BSEP, bile salt export pump; CYP, cytochrome p-450; FXR, farnesoid X receptor; FGF, fibroblast growth factor; GSH, glutathione; MARS, molecular adsorbents recirculation system; MDR3, multidrug resistance-associated protein 3; NTCP, sodium taurocholate cotransporting peptide; OA 2, organic anion; OATP, organic anion transporting polypeptide; OC 1, organic cation; PBC, primary biliary cirrhosis; PL, phospholipid; PPARa, peroxisome proliferator-activated receptor a; PSC, primary sclerosing cholangitis; SLC10A, solute carrier family 10A. From the Department of Internal Medicine, Yale University School of Medicine, New Haven, CT. Potential conflict of interest: Nothing to report. Received 30 July 2016; accepted 25 September 2016 View this article online at wileyonlinelibrary.com VC 2016 by the American Association for the Study of Liver Diseases 140 CLINICAL LIVER DISEASE, VOL 8, NO 6, DECEMBER 2016 An Official Learning Resource of AASLD
2 FIG 1 Molecular determinants of bile formation. Modified from New England Journal of Medicine. 7 Copyright 1998, Massachusetts Medical Society. Abbreviations: A 2, anion; AE2, anion exchange protein 2; BS 2, bile salts; GSH, glutathione; OA 2, organic anion; OATP, organic anion transporting polypeptide; OC 1, organic cation; PL, phospholipid. Food and Drug Administration approved the use of ursodeoxycholic acid for PBC in 2004, the drug has been widely used in other cholestatic disorders and was shown to improve liver tests in primary sclerosing cholangitis (PSC), cholestasis of pregnancy, and cystic fibrosis. It is also used in some cases of drug-induced cholestasis, graft versus host disease, and post-liver transplant cholestasis despite lack of clinical trial evidence of efficacy. 141 CLINICAL LIVER DISEASE, VOL 8, NO 6, DECEMBER 2016 An Official Learning Resource of AASLD
3 FIG 2 Fibrates and cholestasis. Reproduced with permission from Hepatology. 10 Copyright 2015, American Association for the Study of Liver Diseases. Abbreviations: ABCB4, ATP binding cassette family B4; HNF4, hepatocyte nuclear factor 4; IL, interleukin; NF-kB, nuclear factor kappa beta; PC, phosphatidylcholine; TNF-a, tissue necrosis factor-a. Indeed, American Association for the Study of Liver Diseases guidelines do not recommend its use in PSC. Multiple studies have attempted to evaluate its mechanisms of action, which still remain controversial, but include increasing the hydrophilicity of the bile pool, increasing bile flow, thus facilitating the elimination of hydrophobic BAs, stimulating the hydroxylation of more hydrophobic BAs such as lithocholic acid, stimulating exocytosis, and blocking apoptosis. 6 The field of cholestasis was greatly stimulated by the molecular evolution in the mid-1990s, which resulted in elucidating the mechanisms of bile formation and cholestasis at the molecular level 7 (Fig. 1). The clinical relevance of these discoveries was brought home when mutations in canalicular BA and lipid transporters were found to account for the several primary familial intrahepatic cholestasis syndromes (types 1, 11, and 111) in infants, as well as some cases of benign recurrent cholestasis, intrahepatic cholestasis of pregnancy, low-phospholipid-associated cholelithiasis, and some forms of chronic idiopathic cholestatic liver diseases in adults. The next major event came from the nuclear receptor field with the discovery that BAs were the physiological ligands for the previously orphaned farnesoid X receptor (FXR). 8 FXR response elements were soon discovered in bile salt export pump (BSEP), multidrug resistance-associated protein 3 (MDR3), and SHP (an inhibitor of CYP7a, the rate-limiting enzyme in the conversion of cholesterol to BA and NTCP/SLC10A, the conjugated BA uptake transporter, sodium taurocholate cotransporting polypeptide). FXR response elements were also discovered in fibroblast growth factor (FGF) receptors 15 (mice) and 19 (humans) in the ileum. BA activation of these growth factors results in their increased synthesis and release into the portal circulation whereby they interact with the FGF receptor 4/betaklotho complex on the hepatocyte sinusoidal membrane. This interaction sets up a signal transduction pathway leading to the inhibition of CYP7A1 and resultant reduction in BA synthesis and the BA pool. Thus, FXR became recognized as a master regulator of the enterohepatic circulation and a prime therapeutic drug discovery target for cholestatic liver disease. 9 Recent U.S. Food and Drug Administration approval of Intercept Pharma s potent FXR agonist, obeticholic acid, as alternative therapy for PBC is the first clinical outcome of this sequence of discoveries. Another nuclear receptor, peroxisome proliferatoractivated receptor a (PPARa), has also emerged as a potential druggable target for cholestatic liver disease. Fibrates are ligands for the PPARs and a number of clinical studies, predominantly in patients with PBC, have demonstrated significant improvement in alkaline phosphatase after administration of bezafibrate, which activates all three isoforms (PPARa, d, andg). Fenofibrate, a PPARa agonist, also has demonstrated efficacy in patients with PBC. PPARa response elements are prominent in the canalicular membrane phospholipid export pump (MDR3/ABCC4), and the biliary excretion of phosphatidylcholine by this transporter may improve the buffering of BAs in the bile, thereby protecting the biliary tree from bile-acid-induced toxicity. PPARa also inhibits CYP7A1 and BA synthesis, as well as having beneficial anti-inflammatory responses 10 (see Fig. 2). Advances in therapy of patients with primary familial intrahepatic cholestasis syndrome type 2 also have been made where administration of sodium phenyl butyrate seems to act as a chaperone to facilitate targeting of mutant BSEP to the apical membrane in a few patients CLINICAL LIVER DISEASE, VOL 8, NO 6, DECEMBER 2016 An Official Learning Resource of AASLD
4 FIG 3 Different drugs under development for cholestatic liver disease act at different sites. Abbreviation: PL, phosphatidylcholine. FUTURE DIRECTIONS Nevertheless, despite these considerable advances, much remains to be discovered. We still do not know the pathogenesis of either PBC or PSC. Genome-wide association studies in large populations of these patients have not generally led to better understanding of their cause or pathogenesis. An exception may be the FUC1 gene, which regulates intestinal mucous production and where mutations have been discovered in patients with PSC, pointing to possible gut-liver pathogenic mechanisms. Other roadblocks include the lack of good animal models for these diseases and the unlikely possibility that they may be forthcoming. Clinical trials with orphan diseases such as PBC and PSC are often underpowered, and these studies are traditionally lacking in the United States compared with Europe. International collaborations are only just beginning to be developed. What alternative treatments for cholestatic liver disease may emerge in the near future? With an increase in understanding of biliary pathophysiology, new therapeutic advances seem likely. For example, several novel agents are currently in the developmental stage including a variant of FGF-19 that lacks oncogenic activity. This agent inhibits CYP7A1 activity and reduces BA synthesis and is currently being assessed in a phase 2 multicenter trial in primary biliary cholangitis. Inhibitors of the ileal BA transporter modulate BA synthesis and decrease serum BAs. Apical sodium-dependent bile salt transporter (ABST) inhibitors are now in a phase 1 trial in healthy 143 CLINICAL LIVER DISEASE, VOL 8, NO 6, DECEMBER 2016 An Official Learning Resource of AASLD
5 adults. Nor-ursodeoxycholic acid is in phase 2 trials in a multicenter study in patients with sclerosing cholangitis. WHAT ABOUT COMBINATION THERAPIES? Figure 3 illustrates several targets that are amenable to drug therapy but that act at different sites. A key target is CYP7A1 because it regulates the synthesis of BAs and its inhibition results in a diminution of the BA pool size. Drugs including obeticholic acid, FGF-19, and retinoic acid appear to act by this mechanism. Other targets at the level of the hepatocyte include the PPARs. Both bezafibrate and fenofibrate act as pan PPAR isoform and PPARa isoform agonists, respectively, and have been shown to improve liver function tests in PBC and in a few patients with PSC. Another site that regulates BA metabolism is located at the level of the ileum and kidney. Here inhibitors of the ABST in the ileum by A4250 result in increased fecal excretion of BAs, whereas inhibition of ABST in the proximal tubule of the kidney results in increases in urinary BA excretion. It remains to be determined whether combinations of these drugs with or without therapy with UDCA might enhance the anticholestatic properties of these drugs when administered as monotherapy. If we are to achieve answers to these important questions in these lowprevalence cholestatic diseases, a multicenter effort and partnerships with both federal and pharmaceutical sources will be required. ACKNOWLEDGMENT The author expresses his thanks to Carol Soroka, Ph.D., for her critical review of the manuscript and for preparation of Figure 3. CORRESPONDENCE James Boyer, Department of Internal Medicine, Yale University School of Medicine, P.O. Box , New Haven, CT james.boyer@yale.edu REFERENCES 1) Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003;17: ) Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94: ) Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999;41: ) Campli CD, Gaspari R, Mignani V, Stifano G, Santoliquido A, Verme LZ, Proietti R, et al. Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure. Artif Organs 2003;27: ) Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113: ) Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36: ) Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Eng J Med 1998;339: ) Karpen SJ. Bile acids go nuclear! Hepatology 1999;30: ) Cai SY, Boyer JL. FXR: a target for cholestatic syndromes? Expert Opin Ther Targets 2006;10: ) Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 2015;62: ) Gonzalez E, Grosse B, Schuller B, Davit-Spraul A, Conti F, Gueltier C, Cassio D, Jaquemin E. Targeted pharmacotherapy in progressive familiar intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 2015;62: CLINICAL LIVER DISEASE, VOL 8, NO 6, DECEMBER 2016 An Official Learning Resource of AASLD
Hepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationPathophysiology of Bile Secretion
Pathophysiology of Bile Secretion Martin C. Carey, D.Sc., M.D. Division of Gastroenterology, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School Boston, MA, U.S.A. Functions
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationRegulation of the cell surface expression and transport capacity of BSEP by small chemical molecules
Regulation of the cell surface expression and transport capacity of by small chemical molecules Hisamitsu Hayashi and Yuichi Sugiyama Dept. of Molecular Pharmacokinetics, Graduate School of Pharmaceutical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationThe regulation of genes that are essential to many
GASTROENTEROLOGY 2005;129:735 740 NEW CONCEPTS IN GASTROENTEROLOGY Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease? JAMES L. BOYER Liver Center, Department
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationStart Module 2: Physiology: Bile, Bilirubin. Liver and the Lab
Start Module 2: Physiology: Bile, Bilirubin Liver and the Lab Bile Physiology WYNTKFTB (Intro to Pathology) Applied Anatomy Components Function Synthesis Enterohepatic circulation Imbalance of components
More informationPROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
The Childhood Liver Disease Research Network strives to provide information and support to individuals and families affected by liver disease through its many research programs. PROGRESSIVE FAMILIAL INTRAHEPATIC
More informationGenetic cholestasis. Peter Jansen Liver Center Academic Medical Center Amsterdam
Genetic cholestasis Peter Jansen Liver Center Academic Medical Center Amsterdam Genetic cholestasis Proteins and genes Genetic cholestatic diseases Lessons from ko/mutant models A new MDR3 phenotype A
More informationRole of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):
Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):159-234 Drug Metab Rev. 2007;39(1):159-234 Drug Metab Rev. 2007;39(1):159-234 A schematic representation of the most relevant
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationOut-patient albumin dialysis for cholestatic patients with intractable pruritus
Alimentary Pharmacology and Therapeutics Out-patient albumin dialysis for cholestatic patients with intractable pruritus P. Leckie*, G. Tritto*, R. Mookerjee*, N. Davies*, D. Jones & R. Jalan* *Liver Failure
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationPSC: a care-giver s perspective
PSC: a care-giver s perspective PSC Partners Seeking a Cure; Denver, CO; April 30, 2005 David and Judy Rhodes (father and mother of Steven (19); PSC 07/03; UC 08/03) www.psc-literature.org www.pscpartners.org
More informationGrowth analysis in children with PFIC treated with the ASBT inhibitor maralixibat
Growth analysis in children with PFIC treated with the ASBT inhibitor maralixibat INDIGO Study Richard Thompson, Deirdre Kelly, Sanjay Rajwal, Alexander Miethke, Nisreen Soufi, Christine Rivet, Irena Jankowska,
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationDepartment of Internal Medicine and Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27157
thematic review Thematic Review Series: Bile Acids Bile acid transporters Paul A. Dawson, 1 Tian Lan, and Anuradha Rao Department of Internal Medicine and Department of Pathology, Wake Forest University
More informationInhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury
Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Kenneth R. Brouwer, Ph.D., RPh Chief Scientific Officer DDI Meeting June 2017 Seattle, Washington
More informationBile Acids in Cholestasis and its Treatment
53 November, Vol. 16 (Suppl. 1), 2017: s53-s57 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for the
More informationObeticholic acid for the treatment of primary biliary cirrhosis Trivedi, Palak; Hirschfield, Gideon; Gershwin, M Eric
Obeticholic acid for the treatment of primary biliary cirrhosis Trivedi, Palak; Hirschfield, Gideon; Gershwin, M Eric DOI: 0./..0 License: None: All rights reserved Document Version Peer reviewed version
More informationAn Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationDATA SHEET URSOFALK. Ursodeoxycholic Acid
URSOFALK - New Zealand Page 1 of 7 NAME OF DRUG DATA SHEET URSOFALK Ursodeoxycholic Acid DESCRIPTION Ursodeoxycholic acid (UDCA) is a white or almost white powder. It is practically insoluble in water,
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationDepartment of Internal Medicine and the Department of Pathology. Wake Forest University
Bile Acid Transporters Paul A. Dawson, Tian Lan, Anuradha Rao Department of Internal Medicine and the Department of Pathology. Wake Forest University School of Medicine. Winston-Salem, NC 27157 Corresponding
More informationThe many faces of MDR 3 deficiency
The many faces of MDR 3 deficiency Relevance of canalicular membrane transporting proteins for human liver disease Peter LM Jansen and Marleen de Vree Academic Medical Center Amsterdam, The Netherlands
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationProgram Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationAPO-URSODEOXYCHOLIC ACID CAPSULES
APO-URSODEOXYCHOLIC ACID CAPSULES NAME OF THE MEDICINE Ursodeoxycholic Acid (UDCA) Chemical Name: 3α, 7ß-Dihydroxy-5ß-cholan-24-oic acid Structural Formula: Molecular Formula: Molecular Weight: C24H40O4
More informationBile acids, the major constituents of bile, are synthesized
REVIEWS Ursodeoxycholic Acid Therapy in Hepatobiliary Disease Kris V. Kowdley, MD Ursodeoxycholic acid is a hydrophilic bile acid that under normal circumstances represents a small fraction of the bile
More informationBRIDGE THE GAP A Human Pathways Approach to Disease Research
BRIDGE THE GAP A Human Pathways Approach to Disease Research BIOMED 21 Brussels December 8 th, 2015 Brigitte Landesmann Systems Toxicology Unit and EURL ECVAM Institute for Health and Consumer Protection
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationOrganic solute transporter alpha-beta (Ost -
Mouse Organic Solute Transporter Deficiency Enhances Renal Excretion of Bile Acids and Attenuates Cholestasis Carol J. Soroka, 1 Albert Mennone, 1 Lee R. Hagey, 2 Nazzareno Ballatori, 3 and James L. Boyer
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationUniversity of Groningen. Cholesterol, bile acid and triglyceride metabolism intertwined Schonewille, Marleen
University of Groningen Cholesterol, bile acid and triglyceride metabolism intertwined Schonewille, Marleen IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationBile acid metabolism. doc. Ing. Zenóbia Chavková, CSc.
Bile acid metabolism doc. Ing. Zenóbia Chavková, CSc. Bile acid metabolism Importance: Availability for fat & cholesterol absorption Regulates total body pool of cholesterol Factors that synthesis promote
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationREVIEW Nuclear receptors as therapeutic targets in cholestatic liver diseases
British Journal of Pharmacology (2009), 156, 7 27 2008 The Authors Journal compilation 2008 The British Pharmacological Society All rights reserved 0007-1188/08 www.brjpharmacol.org REVIEW Nuclear receptors
More informationCitation for published version (APA): Plass, J. R. M. (2005). Function and regulation of the human bile salt export pump Groningen: s.n.
University of Groningen Function and regulation of the human bile salt export pump Plass, Jacqueline Regina Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if
More informationUniversity of Groningen. The enterohepatic circulation of bile salts in health and disease Hulzebos, Christian Victor
University of Groningen The enterohepatic circulation of bile salts in health and disease Hulzebos, Christian Victor IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationSaul J. Karpen, M.D., Ph.D.
The Re-vival of Bile Acid Based Therapeutics for Children and Adults RXRα FXR Saul J. Karpen, M.D., Ph.D. Raymond F. Schinazi Distinguished Biomedical Chair Professor of Pediatrics HepDart Kona, Hawaii
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationObeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes
ORIGINAL ARTICLE Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes Yuanyuan Zhang 1, Jonathan P. Jackson 2, Robert L. St.
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationReview Article Management of Pruritus in Chronic Liver Disease
Dermatology Research and Practice Volume 2015, Article ID 295891, 5 pages http://dx.doi.org/10.1155/2015/295891 Review Article Management of Pruritus in Chronic Liver Disease Angeline Bhalerao 1 and Gurdeep
More informationRegulating Hepatic Cellular Cholesterol
Under circumstances of cholesterol deficiency, Sterol Regulatory Element Binding Proteins (SREBPs) via binding to DNA nuclear response elements set off genomic production of proteins and enzymes that induce
More informationPrimary biliary cholangitis
A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationDOWNLOAD OR READ : PRIMARY SCLEROSING CHOLANGITIS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : PRIMARY SCLEROSING CHOLANGITIS PDF EBOOK EPUB MOBI Page 1 Page 2 primary sclerosing cholangitis primary sclerosing cholangitis pdf primary sclerosing cholangitis Diagnosis and Management
More informationHepatic bile salt secretion and bile formation. NEW HORIZONS Fibrates and Cholestasis. Nisanne S. Ghonem, 1 David N. Assis, 2 and James L.
NEW HORIZONS Fibrates and Cholestasis Nisanne S. Ghonem, 1 David N. Assis, 2 and James L. Boyer 2 Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results
More informationHepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis Yaping Liu, 1 Jane Binz, 2 Mary Jo Numerick, 3 Steve Dennis, 3 Guizhen Luo, 1 Bhasha Desai,
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More information4. ABSORPTION. Transport mechanisms. Absorption ABSORPTION MECHANISMS. Active transport. Active transport uses metabolic energy
4. ABSORPTION ABSORPTION MECHANISMS Once the digestive process is completed, the nutrients have to be transferred across the digestive tract epithelium into the intracellular space and eventually into
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient. What is OCALIVA? OCALIVA (obeticholic acid) is a prescription
More informationPhase 2 placebo-controlled withdrawal study of the ASBT inhibitor maralixibat in children with Alagille syndrome 48-week efficacy analysis
Phase 2 placebo-controlled withdrawal study of the ASBT inhibitor maralixibat in children with Alagille syndrome 48-week efficacy analysis ICONIC Study Emmanuel Gonzales, Ekkehard Sturm, Michael Stormon,
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationColangitis Esclerosante Primaria: Manejo Clínico y Endoscópico
Colangitis Esclerosante Primaria: Manejo Clínico y Endoscópico Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques Associate Professor
More informationPROGRESS: Beginning to Understand the Genetic Predisposition to PSC
PROGRESS: Beginning to Understand the Genetic Predisposition to PSC Konstantinos N. Lazaridis, MD Associate Professor of Medicine Division of Gastroenterology and Hepatology Associate Director Center for
More informationBecause they are potent detergents, synthesis of bile
High Expression of the Bile Salt-Homeostatic Hormone Fibroblast Growth Factor 19 in the Liver of Patients with Extrahepatic Cholestasis Frank G. Schaap, 1 Niels A. van der Gaag, 2 Dirk J. Gouma, 2 and
More informationBILE FORMATION, ENTEROHEPATIC CIRCULATION & BILE SALTS
1 BILE FORMATION, ENTEROHEPATIC CIRCULATION & BILE SALTS Color index Important Further explanation 2 Mind map...3 Functions of bile & stages of bile secretion... 4 Characteristics & composition of bile...5
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationMechanistic Toxicology
SECOND EDITION Mechanistic Toxicology The Molecular Basis of How Chemicals Disrupt Biological Targets URS A. BOELSTERLI CRC Press Tavlor & France Croup CRC Press is an imp^t o* :H Taylor H Francn C'r,,jpi
More informationPRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationPresentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2015.18.3.202 Pediatr Gastroenterol Hepatol Nutr 2015 September 18(3):202-208 Case Report PGHN Presentation of Progressive Familial Intrahepatic
More informationIn the past decade many new transporters have been SPECIAL REPORTS AND REVIEWS
GASTROENTEROLOGY 2006;130:908 925 SPECIAL REPORTS AND REVIEWS Hepatocanalicular Transport Defects: Pathophysiologic Mechanisms of Rare Diseases RONALD P. J. OUDE ELFERINK, COEN C. PAULUSMA, and ALBERT
More informationACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationBile acids, the water-soluble, amphipathic end products of cholesterol metabolism, are
The Continuing Importance of Bile Acids in Liver and Intestinal Disease Alan F. Hofmann, MD REVIEW ARTICLE Bile acids, the water-soluble, amphipathic end products of cholesterol metabolism, are involved
More informationBile acids initiate cholestatic liver injury by triggering a hepatic specific inflammatory response. Supplementary Results
Bile acids initiate cholestatic liver injury by triggering a hepatic specific inflammatory response Shi-Ying Cai 1, Xinshou Ouyang 1, Yonglin Chen 1, Carol J. Soroka 1, Juxian Wang 2, Albert Mennone 1,
More informationPARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN
PARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN Praveen Goday MBBS CNSC Associate Professor Pediatric Gastroenterology Medical College of Wisconsin Milwaukee, WI Parenteral Nutrition-Associated
More informationIn vertebrates, cholesterol balance is achieved
Bile acids are formed in the pericentral hepatocytes.... Bile Acids: The Good, the Bad, and the Ugly Alan F. Hofmann Bile acids, amphipathic end products of cholesterol metabolism, are good in the infant
More informationYou and OCALIVA (obeticholic acid) The importance of staying on treatment
You and OCALIVA (obeticholic acid) The importance of staying on treatment What is OCALIVA? OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic
More informationChild-Pugh Class B or C or Patients with a Prior Decompensation Event a 5 mg once daily 5 mg once weekly. Compensated Child- Pugh Class A
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCALIVA safely and effectively. See full prescribing information for OCALIVA. OCALIVA (obeticholic
More informationMechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease
Clin Liver Dis 8 (2004) 67 81 Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease Gustav Paumgartner, MD, FRCP*, Ulrich Beuers, MD Department of Medicine
More informationPXR Prevents Cholesterol Gallstone Disease by Regulating Biosynthesis and Transport of Bile Salts
GASTROENTEROLOGY 2011;140:2095 2106 PXR Prevents Cholesterol Gallstone Disease by Regulating Biosynthesis and Transport of Bile Salts JINHAN HE,* SHIGERU NISHIDA, MEISHU XU,* MAKOTO MAKISHIMA, and WEN
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More information